A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned End Date changed from 1 Sep 2022 to 31 Oct 2019.
- 26 Jan 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Oct 2019.